Abraxis Bioscience announced the appointment of Rick Rodgers as Senior Vice President and Chief Financial Officer, succeeding David O'Toole. Rodgers most recently was Senior Vice President, Controller and Chief Accounting Officer of MGI Pharma until the company's acquisition by the Eisai Corporation in 2008.
Boehringer Ingelheim recorded positive growth in the first half of 2025 with an increase in Group sales of 6.3% to € 14 billion.
Novo Nordisk continues its sizeable manufacturing investments to meet increasing drug demands.
MSD, known as Merck & Co. in the US and Canada, recently announced it will acquire Verona Pharma, a biopharmaceutical company focused on respiratory diseases, for approximately $10 billion.
Carbon black manufacturer Orion Engineered Carbons plans to rationalize production lines in North and South America and EMEA.
Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.
